Dimensional Fund Advisors
VERV

Dimensional Fund Advisors’s Verve Therapeutics VERV Stock Holding History

Dimensional Fund Advisors’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-817,532
Closed -$9.18M – 3348
2025
Q2 		$9.18M Buy
817,532
+373,023
+84% +$2.13M ﹤0.01% 2309
2025
Q1 		$2.04M Buy
444,509
+7,420
+2% +$49.7K ﹤0.01% 2724
2024
Q4 		$2.46M Buy
437,089
+5,320
+1% +$30K ﹤0.01% 2734
2024
Q3 		$2.09M Sell
431,769
-4,619
-1% -$26.8K ﹤0.01% 2774
2024
Q2 		$2.13M Sell
436,388
-55,003
-11% -$346K ﹤0.01% 2749
2024
Q1 		$6.53M Buy
491,391
+263,181
+115% +$3.49M ﹤0.01% 2482
2023
Q4 		$3.18M Buy
+228,210
New +$2.83M ﹤0.01% 2674

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Dimensional Fund Advisors's VERV Position: Q3 2025 in Review

Dimensional Fund Advisors sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 817,532 shares — an estimated $9.18M sold.

Dimensional Fund Advisors first reported a position in VERV in Q4 2023 and held it in 7 quarters. The position peaked at $9.18M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Dimensional Fund Advisors reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Dimensional Fund Advisors sold 817,532 Verve Therapeutics shares in Q3 2025, an estimated $9.18M.
  • Dimensional Fund Advisors first reported a position in Verve Therapeutics in Q4 2023 and held it in 7 quarters.
  • Dimensional Fund Advisors's Verve Therapeutics position peaked at $9.18M in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Dimensional Fund Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.